All In Biotech

Drug Trial Radar · NCT05607420

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

Open-label Dose-finding and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)

Last checked: Nov 20, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Nov 1, 2022

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Cellectis S.A.Industry
Sponsor type
Industry
First posted
Nov 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).

Conditions

  • B-cell Non-Hodgkin Lymphoma (B-NHL)

Interventions

  • UCART20x22Biological

    Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen

  • CLLS52Biological

    A monoclonal antibody that recognizes a CD52 antigen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose finding and expansion parts: Incidence of adverse events/serious adverse events/dose limiting toxicity [Safety and Tolerability]Time frame: From study entry through month 12
  2. Dose finding part: Occurrence of Dose Limiting Toxicities (DLTs)Time frame: Up to Day 28 post UCART20x22 infusion

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • The University of Chicago Medical Center (UCMC)

    Chicago, Illinois · Recruiting

  • Harvard Medical School - Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Rutgers Cancer Institute of New Jersey (CINJ) - New Brunswick

    New Brunswick, New Jersey · Recruiting

  • Sarah Cannon - St. David South Austin Medical Center

    Austin, Texas · Recruiting

  • Centre Hospitalier Universitaire de Nantes (CHU de Nantes)-Hotel-Dieu

    Nantes, France · Recruiting

  • Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud

    Pierre-Bénite, Auvergne Rhone Alpe, France · Recruiting

  • Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Saint-Louis - Centre Integre en Cancerologie

    Paris, Île-de-France Region, France · Recruiting

  • Centre Hospitalier Universitaire de Montpellier (CHU Montpellier) - Hopital Saint-Eloi

    Montpellier, Occitanie, France · Recruiting

  • Hospital Universitario Virgen del Rocio (HUVR) - Instituto de Biomedicina de Sevilla (IBIS)

    Seville, Spain · Recruiting

  • Universidad de Navarra - Clinica Universidad de Navarra (CUN) - Pamplona

    Pamplona, Navarre, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.